CSPC Pharmaceutical's (HKG:1093) CPO301 has been granted the third Fast Track designation by the US Food and Drug Administration (FDA) for lung cancer patients, a Monday Hong Kong bourse filing said.
In particular, the designation is for the treatment of adult patients with advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).
"The Fast Track designations in all subtypes of NSCLC were granted based on promising clinical efficacy data," said CSPC.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.